But in our series, after neoadjuvant chemotherapy based on anthracyclines and taxanes, complete pathologic response was estimated as 62% in luminal A, 26% in triple negative breast cancer, and 12% in Her2-overexpressing subtype. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.